A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). This study is seeking participants who: * have breast cancer that is hard to treat and has spread in the body (advanced cancer) * have tumors that have HER2 on them * have received previous treatment for their advanced breast cancer All participants in this study will receive disitamab vedotin at the study clinic once every 2 weeks as an intraven

Trial Details

NCT ID
NCT06966453
Phase
PHASE1 / PHASE2
Sponsor
Pfizer
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Disitamab vedotin
Locations (sample)
  • Daphne, Alabama, United States|30.60353,-87.9036
  • Foley, Alabama, United States|30.40659,-87.6836
  • Mobile, Alabama, United States|30.69436,-88.04305
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Gilbert, Arizona, United States|33.35283,-111.78903

Key Eligibility Criteria

  • Histologically or cytologically confirmed diagnosis of locally-advanced, unresectable, or metastatic breast carcinoma.
  • Human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status appropriate for enrollment in cohort.
  • HER2 status determined by most recent local assessment based on American Society of Clinical Oncology (ASCO) and College of American Pathologists (…
  • HER2+: immunohistochemistry (IHC) 3+ or IHC 2+/in situ hybridization (ISH)+

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →